financetom
Business
financetom
/
Business
/
What's Going On With Emergent BioSolutions Stock Wednesday?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
What's Going On With Emergent BioSolutions Stock Wednesday?
Oct 2, 2024 11:13 PM

Emergent BioSolutions ( EBS ) Inc. stock is trading higher on Wednesday after the company announced the closing of a $100 million asset-backed revolving loan facility.

The Details: The new credit facility is aimed at enhancing Emergent’s liquidity and providing additional financial flexibility to support its operational and strategic initiatives.

At at the end of September, Emergent had a cash balance of about $150 million. Through the new loan facility, Emergent now also has access to up to $100 million in financing.

“We are pleased to have successfully closed on our new ABL credit facility with favorable terms and an extended maturity, which is further evidence of Emergent’s strengthened balance sheet and financial position,” said Joe Papa, president and CEO of Emergent.

How To Buy Emergent BioSolutions Stock

By now you're likely curious about how to participate in the market for Emergent BioSolutions ( EBS ) – be it to purchase shares, or even attempt to bet against the company.

Buying shares is typically done through a brokerage account. You can find a list of possible trading platforms here. Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so.

If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a stock can be found at this resource. Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading – either way it allows you to profit off of the share price decline.

See Also: Tesla Stock Speeds Ahead Of Mag7 Peers, Can October’s Robotaxi Reveal Keep The Momentum?

EBS Price Action: At the time of writing, Emergent BioSolutions ( EBS ) stock is trading 6.49% higher at $9.02, according to data from Benzinga Pro.

Image: 3196481 from Pixabay.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Old National Bancorp strikes $1.4 bln deal for Bremer Financial
Old National Bancorp strikes $1.4 bln deal for Bremer Financial
Nov 25, 2024
Nov 25 (Reuters) - Regional lender Old National Bancorp ( ONB ) said on Monday it will buy privately held Bremer Financial in a $1.40 billion cash-and-stock deal, creating a combined bank with over $70 billion in assets. Bremer shareholders will receive 4.182 shares of Old National and $26.22 in cash, valuing the lender at $116.76 per share. Dealmaking between...
Vertical Aerospace Secures $50 Million Funding Commitment From Primary Creditor and Majority Shareholder
Vertical Aerospace Secures $50 Million Funding Commitment From Primary Creditor and Majority Shareholder
Nov 25, 2024
07:03 AM EST, 11/25/2024 (MT Newswires) -- Vertical Aerospace ( EVTWF ) said Monday it has secured a $50 million funding commitment from primary creditor Mudrick Capital Management and its majority shareholder, Stephen Fitzpatrick who will remain on the board of the company. The funding will support the newly launched Flightpath 2030 Strategy, focusing on its eVTOL market leadership and...
Macy's delays Q3 report on accounting issue, sales misses in preliminary results
Macy's delays Q3 report on accounting issue, sales misses in preliminary results
Nov 25, 2024
(Reuters) - Macy's on Monday delayed publication of its third-quarter results after discovering an accounting issue related to delivery expenses and instead reported preliminary results in which its sales missed Wall Street expectations. Net sales fell 2.4% to $4.74 billion compared to analysts' average estimate of $4.77 billion, as steep promotions failed to attract customers who have turned selective on...
GSK Cancer Therapy Candidate Accepted for FDA Review
GSK Cancer Therapy Candidate Accepted for FDA Review
Nov 25, 2024
07:03 AM EST, 11/25/2024 (MT Newswires) -- GSK (GSK) said Monday that the US Food and Drug Administration has accepted to review a Biologics License Application for its experimental combination therapy to treat multiple myeloma patients who have received at least one prior line of treatment. The company said the application is based on a phase 3 study of blenrep...
Copyright 2023-2026 - www.financetom.com All Rights Reserved